CN103476766B - 杂环化合物和它们作为糖原合酶激酶-3抑制剂的用途 - Google Patents

杂环化合物和它们作为糖原合酶激酶-3抑制剂的用途 Download PDF

Info

Publication number
CN103476766B
CN103476766B CN201180068418.0A CN201180068418A CN103476766B CN 103476766 B CN103476766 B CN 103476766B CN 201180068418 A CN201180068418 A CN 201180068418A CN 103476766 B CN103476766 B CN 103476766B
Authority
CN
China
Prior art keywords
base
urea
quinolyl
pyridine
heterocyclic compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180068418.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103476766A (zh
Inventor
S.C.特纳
H.马克
M.H.M.巴克
M.范加伦
C.霍夫特
W.霍恩贝格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Deutschland GmbH and Co KG
Original Assignee
AbbVie Deutschland GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Deutschland GmbH and Co KG filed Critical AbbVie Deutschland GmbH and Co KG
Publication of CN103476766A publication Critical patent/CN103476766A/zh
Application granted granted Critical
Publication of CN103476766B publication Critical patent/CN103476766B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201180068418.0A 2010-12-30 2011-12-30 杂环化合物和它们作为糖原合酶激酶-3抑制剂的用途 Expired - Fee Related CN103476766B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201061428478P 2010-12-30 2010-12-30
US61/428,478 2010-12-30
US61/428478 2010-12-30
US201161521868P 2011-08-10 2011-08-10
US61/521868 2011-08-10
US61/521,868 2011-08-10
PCT/EP2011/074272 WO2012089828A2 (en) 2010-12-30 2011-12-30 Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Publications (2)

Publication Number Publication Date
CN103476766A CN103476766A (zh) 2013-12-25
CN103476766B true CN103476766B (zh) 2016-08-10

Family

ID=45524498

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180068418.0A Expired - Fee Related CN103476766B (zh) 2010-12-30 2011-12-30 杂环化合物和它们作为糖原合酶激酶-3抑制剂的用途

Country Status (15)

Country Link
US (2) US9090592B2 (enExample)
EP (2) EP2658854B1 (enExample)
JP (2) JP6144201B2 (enExample)
KR (1) KR101860297B1 (enExample)
CN (1) CN103476766B (enExample)
AU (1) AU2011351375B2 (enExample)
BR (1) BR112013016928A2 (enExample)
CA (1) CA2821863A1 (enExample)
IL (1) IL226676A (enExample)
MX (1) MX336346B (enExample)
NZ (1) NZ611314A (enExample)
RU (1) RU2623427C2 (enExample)
SG (2) SG191789A1 (enExample)
WO (1) WO2012089828A2 (enExample)
ZA (1) ZA201304756B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090071662A (ko) * 2006-10-21 2009-07-01 애보트 게엠베하 운트 콤파니 카게 헤테로사이클릭 화합물 및 글리코겐 신타제 키나제 3 억제제로서의 이의 용도
US9266855B2 (en) 2010-09-27 2016-02-23 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) * 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
JP6534098B2 (ja) * 2014-09-12 2019-06-26 国立大学法人 鹿児島大学 成人ｔ細胞白血病治療薬
JP7142022B2 (ja) * 2017-03-08 2022-09-26 コーネル・ユニバーシティー Ｍａｌｔ１の阻害剤およびそれらの使用
RU2739489C2 (ru) * 2018-03-06 2020-12-24 Закрытое Акционерное Общество "Биокад" Новые гетероциклические соединения как ингибиторы CDK8/19
CA3115493A1 (en) * 2018-10-17 2020-04-23 Duke University Quinone reductase 2 inhibitors for use as neuroprotective agents
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
JP2023501208A (ja) * 2019-11-01 2023-01-18 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物的に活性な縮合二環式芳香族複素環式化合物
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
RS66978B1 (sr) 2020-07-02 2025-07-31 Incyte Corp Triciklična jedinjenja uree kao inhibitori jak2 v617f
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
WO2022182839A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
KR20240163688A (ko) 2022-03-17 2024-11-19 인사이트 코포레이션 Jak2 v617f 억제제로서의 삼환계 우레아 화합물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573352A (zh) * 2006-10-21 2009-11-04 艾博特股份有限两合公司 杂环化合物和其作为糖原合酶激酶3抑制剂的用途
CN102015718A (zh) * 2008-04-24 2011-04-13 雅培股份有限两合公司 1-(7-(六氢吡咯并[3,4-c]-吡咯-2(1h)-基)喹啉-4-基)-3-(吡嗪-2-基)脲衍生物和相关的化合物作为糖原合成酶激酶3(gsk-3)

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
DK1019385T3 (da) 1995-09-15 2004-05-24 Upjohn Co Aminoaryloxazolidinon-N-oxider
AUPP003197A0 (en) * 1997-09-03 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
CN1312807A (zh) 1998-06-19 2001-09-12 希龙公司 糖元合成酶激酶3的抑制剂
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
EP1313710A1 (en) 2000-08-31 2003-05-28 Pfizer Products Inc. Pyrazole derivatives and their use as protein kinase inhibitors
ATE346064T1 (de) 2000-09-15 2006-12-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
WO2002102401A1 (en) 2001-04-30 2002-12-27 Zentaris Gmbh Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists
DE10123586A1 (de) 2001-05-08 2002-11-28 Schering Ag 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren
EP1256578B1 (en) 2001-05-11 2006-01-11 Pfizer Products Inc. Thiazole derivatives and their use as cdk inhibitors
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
MXPA04003954A (es) 2001-10-26 2004-11-29 Aventis Pharma Inc Bencimidazoles.
EP2198867A1 (en) 2001-12-07 2010-06-23 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as GSK-3 inhibitors
SE0104341D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New use
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
TW200301123A (en) 2001-12-21 2003-07-01 Astrazeneca Uk Ltd New use
JP4393197B2 (ja) 2001-12-21 2010-01-06 アストラゼネカ・アクチエボラーグ 痴呆関連疾患、アルツハイマー病およびグリコーゲンシンターゼキナーゼ−３関連症状の治療におけるオキシインドール誘導体の使用
SE0200979D0 (sv) 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
US7601718B2 (en) 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
NZ544756A (en) 2003-07-22 2009-09-25 Astex Therapeutics Ltd 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
EP1660467B1 (en) 2003-08-20 2011-12-07 Vertex Pharmaceuticals Incorporated 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazole compounds useful as protein kinase inhibitors
WO2005061516A1 (en) 2003-12-04 2005-07-07 Smithkline Beecham Corporation Novel chemical compounds
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
EP1586318A1 (en) 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
WO2005099353A2 (en) 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
US7452887B2 (en) 2004-06-04 2008-11-18 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2005123672A2 (en) 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
JP2008505167A (ja) 2004-07-05 2008-02-21 アステックス、セラピューティックス、リミテッド 医薬組成物
PL1768967T3 (pl) 2004-07-20 2009-09-30 Symed Labs Ltd Nowe związki pośrednie do wytwarzania linezolidu oraz związki pokrewne
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
EA017545B1 (ru) 2005-06-30 2013-01-30 Янссен Фармацевтика Н.В. Циклические анилино-пиридинотриазины в качестве ингибиторов gsk-3
EP1749523A1 (en) 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 inhibitors
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
AR055669A1 (es) 2005-10-03 2007-08-29 Astrazeneca Ab Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
EP1984370A4 (en) 2006-01-23 2010-03-31 Crystalgenomics Inc PROTEIN KINASE ACTIVITY INHIBITING IMIDAZOPYRIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
US20090221576A1 (en) 2006-02-02 2009-09-03 Astrazeneca Ab Global Intellectual Property Pharmaceutical Use of 2-Hydroxy-3-[5-(Morpholin-4-Ylmethyl) Pyridin-2-YL]-1H-IN-Dole-5-Carbonitrile as a Free Base or Salts
WO2007120102A1 (en) 2006-04-19 2007-10-25 Astrazeneca Ab New substituted oxindole derivatives
EP1849785A1 (en) 2006-04-28 2007-10-31 Neuropharma, S.A. N-(2-Thiazolyl)-amide derivatives as GSK-3 inhibitors
US7622495B2 (en) 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
AU2007333650A1 (en) 2006-12-19 2008-06-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
WO2008077138A1 (en) 2006-12-19 2008-06-26 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
MX2009008465A (es) 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
KR20090129479A (ko) 2007-04-18 2009-12-16 아스트라제네카 아베 화합물 2-히드록시-3-[5-(모르폴린-4-일메틸)피리딘-2-일]1ｈ-인돌-5-카르보니트릴 701의 신규 제조 방법
CA2686545C (en) 2007-04-19 2010-11-02 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
EP1992624A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamide pyrimidone compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
MX2009013213A (es) * 2007-06-08 2010-03-30 Abbott Lab Indazoles 5-sustituidos 5-heteroarilo como inhibidores de cinasa.
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090137457A1 (en) 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
WO2009055006A1 (en) 2007-10-26 2009-04-30 Concert Pharmaceuticals, Inc. Deuterated darunavir
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) * 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573352A (zh) * 2006-10-21 2009-11-04 艾博特股份有限两合公司 杂环化合物和其作为糖原合酶激酶3抑制剂的用途
CN102015718A (zh) * 2008-04-24 2011-04-13 雅培股份有限两合公司 1-(7-(六氢吡咯并[3,4-c]-吡咯-2(1h)-基)喹啉-4-基)-3-(吡嗪-2-基)脲衍生物和相关的化合物作为糖原合成酶激酶3(gsk-3)

Also Published As

Publication number Publication date
KR101860297B1 (ko) 2018-05-23
CN103476766A (zh) 2013-12-25
RU2013135477A (ru) 2015-02-10
SG10201406098UA (en) 2014-11-27
EP2658854A2 (en) 2013-11-06
BR112013016928A2 (pt) 2020-10-27
ZA201304756B (en) 2016-07-27
MX336346B (es) 2016-01-15
US20120172376A1 (en) 2012-07-05
US9540370B2 (en) 2017-01-10
JP2014501269A (ja) 2014-01-20
WO2012089828A3 (en) 2012-09-20
JP6144201B2 (ja) 2017-06-07
NZ611314A (en) 2015-06-26
RU2623427C2 (ru) 2017-06-26
CA2821863A1 (en) 2012-07-05
AU2011351375B2 (en) 2016-08-04
KR20140003518A (ko) 2014-01-09
US20150274724A1 (en) 2015-10-01
JP2017122089A (ja) 2017-07-13
MX2013007702A (es) 2013-11-20
US9090592B2 (en) 2015-07-28
IL226676A (en) 2015-08-31
SG191789A1 (en) 2013-08-30
EP2658854B1 (en) 2017-12-13
AU2011351375A1 (en) 2013-06-20
WO2012089828A2 (en) 2012-07-05
EP3351543A1 (en) 2018-07-25

Similar Documents

Publication Publication Date Title
CN103476766B (zh) 杂环化合物和它们作为糖原合酶激酶-3抑制剂的用途
EP2411379B1 (en) Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
CN103119035B (zh) 杂环化合物和它们作为糖原合成酶激酶-3抑制剂的用途
ES2445791T3 (es) Compuestos hetererocíclicos y su uso como inhibidores de la glucógeno sintasa cinasa 3
JP5756011B2 (ja) グリコーゲン合成酵素キナーゼ３（ｇｓｋ−３）としての１−（７−（ヘキサヒドロピロロ［３，４−ｃ］ピロール−２（１ｈ）−イル）キノリン−４−イル）−３−（ピラジン−２−イル）尿素誘導体とその関連化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160810

Termination date: 20181230

CF01 Termination of patent right due to non-payment of annual fee